Radiopharm Theranostics (ASX:RAD) Net Margin %: -872.25% (As of Jun. 2025)


What is Radiopharm Theranostics Net Margin %?

Radiopharm Theranostics ASX:RAD -5.00% Net Margin % is -872.25% as of Jun. 2025. The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Radiopharm Theranostics ranks worse than 79.3% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Radiopharm Theranostics's Net Income for the six months ended in Jun. 2025 was A$-19.62 Mil. Radiopharm Theranostics's Revenue for the six months ended in Jun. 2025 was A$2.25 Mil. Therefore, Radiopharm Theranostics's net margin for the quarter that ended in Jun. 2025 was -872.25%.

The historical rank and industry rank for Radiopharm Theranostics's Net Margin % or its related term are showing as below:

ASX:RAD' s Net Margin % Range Over the Past 10 Years
Min: -337100   Med: -13944.77   Max: -1055.38
Current: -1055.38

ASX:RAD's Net Margin % is ranked worse than
79.3% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs ASX:RAD: -1055.38

Radiopharm Theranostics  (ASX:RAD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Radiopharm Theranostics Net Margin % Related Terms

Radiopharm Theranostics Net Margin % Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Net Margin % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Net Margin %
-337,100.00 -11,853.08 -16,036.45 -1,055.38

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial 0.00 0.00 -8,119.40 -1,352.96 -872.25

ASX:RAD vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Net Margin % falls into.


Radiopharm Theranostics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Radiopharm Theranostics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-38.342/3.633
=-1,055.38 %

Radiopharm Theranostics's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-19.617/2.249
=-872.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -872.25% mean?
Radiopharm Theranostics (ASX:RAD) has a Net Margin % of -872.25% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #751 out of 947 companies in the Biotechnology industry, placing it in the top 79.3%.
Is Radiopharm Theranostics' Net Margin % too high?
Radiopharm Theranostics' current Net Margin % is -872.25%. Based on the distribution chart, Radiopharm Theranostics ranks #751 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #751 out of 947 companies for Net Margin %. This places Radiopharm Theranostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Net Margin % is -872.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Net Margin % of -872.25%. The current Net Margin % is -872.25%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Net Margin % is -872.25% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.